Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Koch

Showing results (651-660 of 672) with videos related to

Pageof 68
Sort By:
The Journal of Invasive Cardiology|October 5, 2021
The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve ReplacementThomas P W van den Boogert, Jeroen Vendrik, Jetske L B Gunster, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
International Journal of Cardiology|September 13, 2019
A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trialLaura S M Kerkmeijer, Ruben Y G Tijssen, Sjoerd H Hofma, et al.
Medrxiv : the Preprint Server for Health Sciences|May 13, 2022
Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1Kyle G Rodino, David R Peaper, Brendan J Kelly, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 11, 2019
Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudyRuben Y G Tijssen, Rene J van der Schaaf, Robin P Kraak, et al.
Lancet (London, England)|December 6, 2017
A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trialRobbert J de Winter, Yuki Katagiri, Taku Asano, et al.
JACC. Cardiovascular Interventions|February 8, 2018
A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE TrialJan Baan, Bimmer E Claessen, Kirsten Boerlage-van Dijk, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 30, 2014
Head-to-head comparison of basal stenosis resistance index, instantaneous wave-free ratio, and fractional flow reserve: diagnostic accuracy for stenosis-specific myocardial ischaemiaTim P van de Hoef, Martijn Meuwissen, Javier Escaned, et al.
Cancers|February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or ToxicityElias A T Koch, Anne Petzold, Anja Wessely, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Survey of white-footed mice in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronavirusesRebecca Earnest, Anne M Hahn, Nicole M Feriancek, et al.
Pageof 68

Showing results (651-660 of 672) with videos related to

Sort By:
Pageof 68
The Journal of Invasive Cardiology|October 5, 2021
The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve ReplacementThomas P W van den Boogert, Jeroen Vendrik, Jetske L B Gunster, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
International Journal of Cardiology|September 13, 2019
A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trialLaura S M Kerkmeijer, Ruben Y G Tijssen, Sjoerd H Hofma, et al.
Medrxiv : the Preprint Server for Health Sciences|May 13, 2022
Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1Kyle G Rodino, David R Peaper, Brendan J Kelly, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 11, 2019
Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudyRuben Y G Tijssen, Rene J van der Schaaf, Robin P Kraak, et al.
Lancet (London, England)|December 6, 2017
A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trialRobbert J de Winter, Yuki Katagiri, Taku Asano, et al.
JACC. Cardiovascular Interventions|February 8, 2018
A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE TrialJan Baan, Bimmer E Claessen, Kirsten Boerlage-van Dijk, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 30, 2014
Head-to-head comparison of basal stenosis resistance index, instantaneous wave-free ratio, and fractional flow reserve: diagnostic accuracy for stenosis-specific myocardial ischaemiaTim P van de Hoef, Martijn Meuwissen, Javier Escaned, et al.
Cancers|February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or ToxicityElias A T Koch, Anne Petzold, Anja Wessely, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Survey of white-footed mice in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronavirusesRebecca Earnest, Anne M Hahn, Nicole M Feriancek, et al.
Pageof 68